Posted by Michael Wonder on 23 Apr 2022
Quanterix granted breakthrough device designation from U.S. FDA for NfL test for multiple sclerosis
22 April 2022 - Blood based assay has the potential to serve the multiple sclerosis community in management of relapsing-remitting form of the disease.
Quanterix Corporation today announced that its Simoa neurofilament light chain (NfL) plasma test has been granted breakthrough device designation by the U.S. FDA as a prognostic aid in assessing the risk of disease activity in patients diagnosed with relapsing-remitting multiple sclerosis.
